Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s flagship product candidates include Atrioventricular Interval Modulation (AVIM) therapy (BackBeat CNT) for the treatment of hypertension, the leading risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic coronary artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn and Twitter.
![Orchestra BioMed logo](/files/LOGO/1814114-OBIO.png)
Company profile
Ticker
OBIO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Health Sciences Acquisitions Corp 2
SEC CIK
Corporate docs
Subsidiaries
HSAC Olympus Merger Sub, Inc. ...
OBIO stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 24
8-K
Regulation FD Disclosure
11 Jun 24
EFFECT
Notice of effectiveness
28 May 24
424B3
Prospectus supplement
24 May 24
S-3
Shelf registration
15 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
EFFECT
Notice of effectiveness
10 May 24
424B3
Prospectus supplement
9 May 24
ARS
2023 FY
Annual report to shareholders
30 Apr 24
DEFA14A
Additional proxy soliciting materials
30 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.32 mm | 23.32 mm | 23.32 mm | 23.32 mm | 23.32 mm | 23.32 mm |
Cash burn (monthly) | 2.41 mm | (no burn) | 4.81 mm | 4.53 mm | 4.37 mm | 3.74 mm |
Cash used (since last report) | 9.32 mm | n/a | 18.59 mm | 17.52 mm | 16.90 mm | 14.45 mm |
Cash remaining | 14.00 mm | n/a | 4.74 mm | 5.80 mm | 6.42 mm | 8.87 mm |
Runway (months of cash) | 5.8 | n/a | 1.0 | 1.3 | 1.5 | 2.4 |
Institutional ownership, Q1 2024
28.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 9 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.27 bn |
Total shares | 10.36 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HSAC 2 | 5.11 mm | $0.00 |
MDT Medtronic | 5.00 mm | $0.00 |
TD Asset Management | 92.68 k | $488.41 mm |
HighTower Advisors | 53.00 k | $280.00 mm |
Arkadios Wealth Advisors | 51.60 k | $271.91 mm |
BK Bank Of New York Mellon | 32.78 k | $172.73 mm |
SEIC SEI Investments | 10.29 k | $54.23 mm |
New York State Common Retirement Fund | 4.20 k | $22.00 k |
Amalgamated Bank. | 141.00 | $1.00 k |
Nisa Investment Advisors | 4.00 | $21.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Jun 24 | Hochman David P | Common Stock, par value $0.0001 per share ("Common Stock") | Buy | Acquire P | Yes | No | 6.95 | 1,000 | 6.95 k | 333,502 |
20 Jun 24 | Pacitti David | Common Stock, par value $0.0001 per share ("Common Stock") | Grant | Acquire A | No | No | 0 | 5,376 | 0.00 | 17,546 |
20 Jun 24 | Pacitti David | Stock Option Common Stock | Grant | Acquire A | No | No | 7.44 | 17,068 | 126.99 k | 17,068 |
20 Jun 24 | Rose Eric A MD | Common Stock, par value $0.0001 per share ("Common Stock") | Grant | Acquire A | No | No | 0 | 5,376 | 0.00 | 7,544 |
20 Jun 24 | Rose Eric A MD | Stock Option Common Stock | Grant | Acquire A | No | No | 7.44 | 17,068 | 126.99 k | 17,068 |
20 Jun 24 | Eric S Fain | Common Stock, par value $0.0001 per share ("Common Stock") | Grant | Acquire A | Yes | No | 0 | 5,376 | 0.00 | 46,810 |
20 Jun 24 | Eric S Fain | Stock Option Common Stock | Grant | Acquire A | Yes | No | 7.44 | 17,068 | 126.99 k | 17,068 |
News
B. Riley Securities Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15
25 Jul 24
Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
12 Jun 24
Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate
13 May 24
12 Health Care Stocks Moving In Thursday's After-Market Session
2 May 24